# A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer

> **NCT00417885** · PHASE1,PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 6 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** exemestane
- **DRUG:** sunitinib malate

## Key facts

- **NCT ID:** NCT00417885
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-06
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** See Detailed Description for Termination Reason
- **Last updated:** 2010-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00417885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00417885, "A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00417885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*